Treatment with AISA-021 (cilnidipine), being developed by Aisa Pharma for Raynaud’s phenomenon, safely reduced the frequency and duration of Raynaud’s attacks in people with systemic sclerosis (SSc). That’s according to recently reported results from the Phase 2 RECONNOITER-1 trial (ACTRN12621000459820) — data that also showed that the…
News
Hand baths enriched with carbon dioxide (CO2) — a gas that exists naturally in the atmosphere, and is produced by living things breathing out — can significantly widen blood vessels of the fingers in people with systemic sclerosis (SSc)-associated Raynaud’s phenomenon. That’s according to a small clinical trial…
The use of immunosuppressive and combination treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) has increased significantly over the past two decades, with more than half of patients now starting treatment at their first evaluation, according to a new study. Over the same period, rates of…
Levels of soluble CD13, the circulating form of a protein involved in inflammation and fibrosis (scarring), are generally higher in people with scleroderma, but do not clearly correlate with disease severity or specific clinical features, a new study reports. The findings suggest that CD13 alone is unlikely to serve…
Mesenchymal stem cells (MSCs) — a type of regulatory cell found in various tissues — work to reduce lung scarring in systemic sclerosis (SSc) by suppressing the growth of certain immune T-cells that carry the PD-1 receptor, according to a new study. PD-1 is an immune checkpoint protein…
Macrophages, a type of immune cell, may be mainly responsible for driving fibrosis, or scarring, in people with scleroderma, according to new research done in animal models. “These data suggest that a single cell type, macrophage, may be responsible for inducing scleroderma,” Sanja Arandjelovic, PhD, who co-led the study…
Abnormal fatty acid metabolism may play a role in the development of systemic sclerosis (SSc), according to a gene activity analysis. Researchers identified three genes involved in fatty acid metabolism that were significantly dysregulated in SSc patients. These changes correlated with markers of fat metabolism and disease complications, including…
Carbon dioxide ablative fractional laser (CO2-AFL) therapy, a treatment that’s long been used to remove wrinkles, may help reduce skin scarring in people with localized scleroderma, according to a new study. “Overall, CO2-AFL treatment appears to have good therapeutic effects in patients with [localized scleroderma], especially patients who are…
Lower blood levels of immunoglobulin G (IgG), an antibody measured through routine blood tests, were linked to poorer health-related quality of life in people with systemic sclerosis (SSc), including greater pain, reduced physical function, and higher overall disease burden, a study reports. These findings suggest that blood IgG levels…
Having anti-SSA antibodies, without other common scleroderma-related antibodies present, is linked to shorter survival and faster disease progression in people with systemic sclerosis (SSc), according to a recent study from Japan. “These findings support the inclusion of anti-SSA in routine serologic [blood] assessment and underscore the potential utility of…
Recent Posts
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research
- Study maps shift in prescribing patterns as guidelines evolve
- Blood protein may help predict lung decline in scleroderma-related ILD